BrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024
BURLINGTON, Mass. and JERUSALEM, July 23, 2024 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”),...
Neuroscience
Ovid Therapeutics Expands Scientific Advisory Board with Appointments of Leading Neurologists, Neuroscientists and Epileptologists
Group to Advise on the Application of Ovid’s Novel Pipeline Programs to Broader Disorders of the BrainNeurologists/epileptologists Dr. Imad Najm...
Reunion Neuroscience Inc. Announces First Patient Dosed in Phase 2 Clinical Trial of RE104 for the Treatment of Postpartum Depression
MORRISTOWN, N.J., July 23, 2024 (GLOBE NEWSWIRE) -- Reunion Neuroscience Inc., a clinical-stage biopharmaceutical company committed to pushing the boundaries...
MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine’s Drug Resistance
New findings highlight potential advantages of MIRA's novel oral ketamine analog for treating neurological and neuropsychiatric disorders MIAMI, FL /...
Aetna Policy Update Expands TMS Availability for Adolescents With Depression
Coverage criteria consistent with recent FDA clearance for NeuroStar TMSMALVERN, Pa., July 22, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ:...
GlassView Taps Amazon Ads’ Stellantis US Agency & Enterprise Lead as VP, Client Partnerships
NEW YORK, July 19, 2024 /PRNewswire/ -- With a 20 year career in producing data-driven solutions for clients at Amazon...
New data for Roche’s Susvimo demonstrates sustained efficacy in two serious diabetic eye conditions
Two-year Phase III data presented at ASRS 2024 show Susvimo’s potential as an alternative to eye injections to treat diabetic...
Novartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up...
Venture-Backed The Way Launches First-of-Its-Kind Meditation Training App
Taught by renowned Zen Master and author Henry Shukman, new app offers program of long-term meditation training that guides users...
Cumulus Neuroscience to Present Data at AAIC 2024 Annual Meeting and Technology and Dementia Preconference
Full analysis of first-in-class CNS-101 study measuring functional neurophysiology at home in patients living with mild Alzheimer's dementiaPoster presentations scheduled for the...
Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives
Rick Barry appointed Executive Chairman of the BoardRemi Barbier resigns as President and CEO and from the Board of DirectorsCassava...
ONWARD® Medical Publishes Annual Sustainability Summary
Company strengthens sustainability practices prior to commercializationEINDHOVEN, the Netherlands, July 17, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD),...
ShiraTronics Unveils Data on their Neurostimulation System for Chronic Migraine
MIAMI BEACH, Fla., July 16, 2024 /PRNewswire/ -- ShiraTronics, a trailblazing clinical-stage neurostimulation company, proudly presented findings from its Australian...
Algernon Pharmaceuticals Reports Results of Study Showing 93% Cough Suppression with Ifenprodil
VANCOUVER, British Columbia, July 16, 2024 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or...
Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC
Testing confirms MIRA's preliminary beliefs regarding potential treatment for neurological and neuropsychiatric disorders MIAMI, FL / ACCESSWIRE / July 15,...
10x Genomics to Report Second Quarter 2024 Financial Results on August 8, 2024
PLEASANTON, Calif., July 12, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today...
Algernon Pharmaceuticals Announces Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia, July 11, 2024...
Cumulus Neuroscience to Join Bio-Hermes 2 Study with Funding from the Innovate UK Small Business Research Initiative (SBRI) Dementia Mission Project
Funded by a nearly £1.2M (~$1.5M USD) award, this research will enable ongoing validation of AccelADx™, a breakthrough screening test for...
CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024
Phase 2b RewinD-LB trial of neflamapimod for the treatment of dementia with Lewy bodies is fully enrolled with topline data...
California Medicaid Adds TMS Access for 14.8 Million Adolescents and Adults
NeuroStar, the first and only TMS treatment cleared for adolescents, now covered by Medi-CalMALVERN, Pa., July 11, 2024 (GLOBE NEWSWIRE)...